SummaryIsomorphic Labs, a London-based AI-driven drug discovery company spun out of Google DeepMind, raised a $5 billion Series C round co-led by Sequoia and Greenoaks. The company will use this investment, coming just six months after its $2.1 billion Series B, to scale its proprietary drug design engine and advance candidates into clinical trials. |
Why it mattersInvesting $5 billion in a company whose core assets are still in the preclinical stage highlights the massive capital attraction of the thesis that AI plays a pivotal role in biology. The simultaneous participation of Alphabet, GV, and CapitalG underscores Isomorphic's deep ties to the Google/DeepMind ecosystem. This pace, raising over $7 billion in roughly six months, sets a new benchmark for AI-biotech valuations and may force competitors to either match this velocity or risk falling behind. |
Highlights- A $5 billion Series C round co-led by Sequoia and Greenoaks, with participation from a16z, Thrive, Alphabet/GV/CapitalG, Temasek, and a Sovereign AI fund
- The company is still moving candidates into their first clinical trials; there are no approved therapeutic products yet
- Funds are allocated to scaling the IsoDDE engine, developing foundational biology models, and building clinical infrastructure
|
Critical takeThe article reads almost entirely like a press release. Every concrete claim is attributed to Hassabis or Jaderberg. There is no independent commentary on scientific risks, the competitive landscape, or whether the extraordinary capital velocity (over $7 billion in about six months) reflects genuine pipeline progress or merely the gravitational pull of the DeepMind/Alphabet brand. The triple participation of the Alphabet family (Alphabet, GV, CapitalG) also blurs the line between an independent startup and an internal Google project. The article fails to question this tension at all. |
This critique was written by the local AI model
Qwen3.8-27B. I chose the story; I do not review each critique before it is published.